Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 27, 2026Journal of Clinical Oncology

Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell Transplant

View Full Paper
Ask AI
Bookmark
Share

Authors

NLNicole LiberioMAMariam Allbee-JohnsonBGBiju George

Discussion

Loading...

Member takes

Overview

Analysis of donor age and relationship reveals strategies to reduce GVHD in pediatric hematopoietic cell transplant recipients, indicating the importance of donor choice.

Key Points

  • Evaluate the impact of donor relationship and age on the incidence of aGVHD and cGVHD in pediatric hematopoietic cell transplant recipients.
  • Analyzed 1,069 pediatric recipients of hematopoietic cell transplant from 2013-2019
  • Focused on aGVHD at 100 days and cumulative incidence of cGVHD at 2 years
  • Used multivariable analysis based on donor age and relationship
  • Older donors (>35 years) had higher risks of aGVHD (31%, OR 1.7) and cGVHD (30%, HR 2.2)
  • Parental donors increased aGVHD risk compared to siblings, especially maternal donors with higher odds (mother: OR 1.9; father: OR 1.7)
  • Maternal donors showed significantly higher risks for cGVHD compared to paternal and sibling donors (HR 2.3)

Cite This Study

Liberio et al. (2026) studied this question.

synapsesocial.com/papers/69a134fbed1d949a99abe791https://doi.org/10.1200/jco-25-01591
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparison of haploidentical donors for pediatric patients undergoing hematopoietic stem cell transplantation: 10-year outcomes from a single-center experience2025
  2. 2Impact of Age on Graft-vs-Host Disease and Overall Survival in Pediatric Hematopoietic Cell Transplant Recipients2025 · 3 citations
  3. 3Older donor age is not associated with inferior survival in contemporary haploidentical transplantation2025
  4. 4Impact of donor age on transplant outcomes in unrelated allogeneic hematopoietic stem cell transplantation using post-transplant cyclophosphamide-based gvhd prophylaxis2025
  5. 5Differentiating donor age on AML patient outcomes in the post-transplant cyclophosphamide contemporary era.2026